has been refreshed! Take a tour.

Ask the Experts: Meningococcal ACWY: Administering Vaccines

Results (4)

The “two-vial” formulation of Menveo (MenACWY-CRM, GSK) requires reconstitution of a lyophilized powder with a diluent: it is FDA-licensed for administration to individuals age 2 months through 55 years. The “one-vial” liquid formulation of Menveo licensed in 2022 is essentially the same vaccine, but does not require reconstitution before administration; however, this formulation is currently licensed only for administration to people age 10 through 55 years.

If the “one-vial” formulation is inadvertently administered to a child younger than age 10 years, this incident should be reported to the Vaccine Adverse Event Reporting System (VAERS, as a vaccine administration error; however, the dose may be counted as valid and should not be repeated. If your facility stocks both one-vial and two-vial Menveo formulations, review practices and protocols and ensure clear labeling of vaccines in storage units to minimize the risk of administering the one-vial formulation to a child younger than age 10 years.

Note that administration of a dose of either Menveo formulation or Menactra (MenACWY-D, Sanofi) to a patient who is older than the FDA-licensed upper age limit of 55 years should not be reported to VAERS and is not considered an error. This is because ACIP recommendations state that Menveo or Menactra may be administered to adults age 56 or older when MenACWY vaccination is indicated and MenQuadfi (MenACWY-TT, Sanofi, licensed with no upper age limit) is not available.

Last reviewed: August 23, 2023

All meningococcal conjugate vaccines (MenACWY, MenB) should be administered by the intramuscular route.

Last reviewed: July 15, 2023

The liquid vaccine component (the diluent) of Menveo contains the C, W-135, and Y serogroups, and the lyophilized vaccine component (the freeze-dried powder) contains serogroup A. Because the patient received only the diluent, he or she is not protected against invasive meningococcal disease caused by N. meningitidis serogroup A.

Invasive disease with N. meningitidis serogroup A is very rare in the United States, but is more common in some other countries. If the recipient (of the C-Y-135 “diluent” only) is certain not to travel outside the United States then the dose does not need to be repeated. However, if the recipient plans to travel outside the United States the dose should be repeated with correctly reconstituted Menveo, the one-vial formulation of Menveo that does not require reconstitution, or with a dose of another brand of MenACWY. There is no minimum interval between the incorrect dose and the repeat dose.

Last reviewed: July 15, 2023

Yes. MenACWY and MenB vaccines can be given at the same visit or at any time before or after the other.

Last reviewed: July 15, 2023

This page was updated on .